Last reviewed · How we verify
NCT06614088
Serum Calprotectin in Surgical Septic Patients
trial testing serum calprotectin in Infection, Intraabdominal in 150 participants. Currently enrolling.
1 November 2024
Quick facts
| Lead sponsor | Azienda Ospedaliero, Universitaria Pisana |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 November 2021 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- serum calprotectin
Conditions studied
- Infection, Intraabdominal — all drugs for Infection, Intraabdominal →
- Sepsis Abdominal — all drugs for Sepsis Abdominal →
- Biomarker — all drugs for Biomarker →
Sponsor
Azienda Ospedaliero, Universitaria Pisana — full company profile →
Who can join
18 and older, any sex, with Infection, Intraabdominal or Sepsis Abdominal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To early evaluate the serum levels of calprotectin in patients suffering from intra-abdominal sepsis requiring a surgical treatment. The research project aims to investigate the role of serum calprotectin in the diagnosis of sepsis and to establish whether its level significantly correlates with different degree of disease severity and with short and long-term outcomes. If these associations were confirmed, serum calprotectin would represent an easily and rapidly detectable biomarker able to predict the severity of sepsis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06614088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Azienda Ospedaliero, Universitaria Pisana trials
Trials by the same sponsor.
- NCT07512453 — Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration · not yet recruiting
- NCT06333132 — Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat) · NA · unknown
- NCT07250607 — Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications · active not recruiting
- NCT07132086 — Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting · completed
- NCT06876948 — NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencep · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06614088 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero, Universitaria Pisana
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06614088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing